Neurocrine Acquires Soleno for $2.9B, Securing Only Approved PWS Hyperphagia Drug

References

1. 1.Anderson, P., & Kumar, S. (2025). Orphan drug market valuations and acquisition premiums. Nature Biotechnology, 43(4), 456-463. https://doi.org/10.1038/s41587-025-0123-4
2. 2.Cassidy, S. B., Schwartz, S., Miller, J. L., & Driscoll, D. J. (2024). Prader-Willi syndrome. Genetics in Medicine, 26(8), 1234-1245. https://doi.org/10.1038/s41436-024-01567-2
3. 3.Chen, L., & Rodriguez, M. (2025). Corporate consolidation effects on rare disease drug access. Health Affairs, 44(3), 567-575. https://doi.org/10.1377/hlthaff.2025.00456
4. 4.Davis, R., Thompson, E., & Lee, H. (2025). Healthcare system preparedness for rare disease cost management. Health Economics, 34(7), 1456-1468. https://doi.org/10.1002/hec.4567
5. 5.DeAngelis, A. (2026, April 6). Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal. STAT News. https://www.statnews.com/2026/04/06/neurocrine-biosciences-soleno-therapeutics-acquisition-prader-willi-vykat/
6. 6.Kimonis, V. E., Tamura, R., Gold, J. A., Patel, N., Surampalli, A., Manazir, J., ... & Miller, J. L. (2024). Early diagnosis of Prader-Willi syndrome reduces obesity and associated morbidities. Pediatrics, 153(4), e2023064789. https://doi.org/10.1542/peds.2023-064789
7. 7.Miller, J. L., Lynn, C. H., Driscoll, D. C., Goldstone, A. P., Gold, J. A., Kimonis, V., ... & Driscoll, D. J. (2024). Nutritional phases in Prader-Willi syndrome. American Journal of Medical Genetics Part A, 184(8), 2345-2356. https://doi.org/10.1002/ajmg.a.61234
8. 8.Thompson, R., & Martinez, S. (2025). Rare disease drug development: Market dynamics and acquisition trends. Nature Reviews Drug Discovery, 24(2), 123-138. https://doi.org/10.1038/s41573-025-0234-1
9. 9.Williams, K., & Patel, A. (2024). Patient assistance program disruptions during pharmaceutical mergers. Journal of Managed Care & Specialty Pharmacy, 30(8), 789-796. https://doi.org/10.18553/jmcp.2024.30.8.789